Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. 3,4-Diaminopyridine enhances the release of acetylcholine at the neuromuscular synapse, and pyridostigmine inhibits the degradation of this neurotransmitter. Although this could lead to a synergistic effect on neuromuscular transmission, no studies have compared the effects of these drugs in patients with LEMS. Therefore, we performed a placebo-controlled, double-dummy, double-blind, randomized, crossover study in nine patients with LEMS.
Wirtz
P W
PW
Department of Neurology, Haga Hospital, The Hague, The Netherlands. p.wirtz@hagaziekenhuis.nl
Verschuuren
J J
JJ
van Dijk
J G
JG
de Kam
M L
ML
Schoemaker
R C
RC
van Hasselt
J G C
JG
Titulaer
M J
MJ
Tjaden
U R
UR
den Hartigh
J
J
van Gerven
J M A
JM
D015761:4-Aminopyridine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D000077770:Amifampridine; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D053580:Muscle Strength / Q000187:drug effects / Q000502:physiology; D011729:Pyridostigmine Bromide / Q000008:administration & dosage*; D016896:Treatment Outcome
D015761:4-Aminopyridine; D011729:Pyridostigmine Bromide; D000077770:Amifampridine